Markets:

Overview

News

Currencies

International

Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

1.740 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Mar 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2

...

29 30 31 32 33 34 35 36 Next >

FDA May Not Review New COVID-19 Vaccine Emergency Use Requests ↗

May 26, 2021

The FDA, on Tuesday, said that it might decline to review and process new emergency use authorization (EUA) requests for COVID-19 vaccines for the rest of the pandemic...

Via Benzinga

Bharat Biotech's US Partner Ocugen Submits Covaxin Master File for FDA Review ↗

May 25, 2021

Ocugen Inc (NASDAQ: OCGN), India-based Bharat Biotech’s U.S. partner for COVID-19 vaccine Covaxin, has submitted a “Master File” to the FDA...

Via Benzinga

Take Profits If You Own Ocugen Stock, but Now’s Not the Time to Buy ↗

May 24, 2021

We don't know if the FDA will authorize emergency use for Covaxin. Therefore OCGN stock is a high risk investment.

Via InvestorPlace

Ocugen vs. Inovio: Where Is the Smart Money Going? ↗

May 23, 2021

They're both seeking share in the vaccine market.

Via The Motley Fool

Ocugen Faces Long Odds Before Gaining From Its Covid-19 Support Role ↗

May 21, 2021

Ocugen has skin in the Covid-19 vaccine game. But the company faces long odds on its partnership providing a long-term boost for OCGN stock.

Via InvestorPlace

Stay On The Sidelines With Ocugen Stock ↗

May 19, 2021

The small biopharmaceutical company has a promising Covid-19 vaccine, but the timing of its approval remains a question mark for OCGN stock.

Via InvestorPlace

Ocugen Stock Is Left Behind As the U.S. Emerges From the Pandemic ↗

May 17, 2021

There seems to be no need for Covaxin in the U.S. and there are no indications that the U.S. is considering approving it. Consequently, OCGN stock is worth shorting.

Via InvestorPlace

Will Covaxin's Success Against COVID Variants Make Ocugen a Big Winner? ↗

May 15, 2021

It's still really early.

Via The Motley Fool

Ocugen or Vaxart: Which Will Take Investors Further? ↗

May 15, 2021

These two high-flying biotechs are vying for the same market.

Via The Motley Fool

Ocugen Has a Longer Road To Paying off Than People Think ↗

May 13, 2021

Even after good news in recent days, OCGN stock is right back where it started. And that still doesn't create a buying opportunity.

Via InvestorPlace

Can Ocugen Overcome This Major Hurdle? ↗

May 13, 2021

It will determine whether the shares sink or skyrocket in the long term.

Via The Motley Fool

Take a Look at Ocugen’s Work on Eye Diseases, Not Just Their Vaccine Partnership ↗

May 11, 2021

With clinical data to support Ocugen's product candidate to treat multiple eye conditions, OCGN stock isn't just your typical "vaccine stock."

Via InvestorPlace

Could Ocugen Be a Millionaire Maker Stock? ↗

May 11, 2021

This coronavirus vaccine drugmaker has made investors rich in a very short period. Can it sustain its run?

Via The Motley Fool

FDA To Hold AdCom Meeting For Expanding Use COVID-19 Vaccine In Children ↗

May 10, 2021

The FDA’s Center for Biologics Evaluation and Research (CBER) will convene a virtual meeting of the Vaccines and Related Biological Products Advisory Committee on June 10...

Via Benzinga

This Is Why Ocugen Crashed Despite Apparent Good News ↗

May 10, 2021

Ocugen released a bunch of seemingly positive news in recent days. Yet OCGN stock tanked anyway. Here's why you should stay away from it.

Via InvestorPlace

3 Investments That Turned $35,000 Into $1 Million (or More) in Just 6 Months ↗

May 08, 2021

One security grew $35,000 into more than $9 million since early November.

Via The Motley Fool

Topics Stocks

Ocugen, Inc. (OCGN) Q1 2021 Earnings Call Transcript ↗

May 07, 2021

OCGN earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

OCGN Stock: Why Red-Hot Ocugen Is Plunging Again Today ↗

May 07, 2021

Ocugen (OCGN) stock taking a beating on Friday following the release of the biopharmaceutical company's earnings report for Q1 2021.

Via InvestorPlace

Why Ocugen Stock Is Tanking Today ↗

May 07, 2021

Investors didn't get what they wanted in the biotech's Q1 update.

Via The Motley Fool

Ocugen Stock Has a Big Pullback Coming, and That Will Be Your Chance ↗

May 07, 2021

OCGN Stock had a nice run in recent weeks but faces risks of a sharp pullback that could lead to paper losses for speculators.

Via InvestorPlace

Ocugen Stock Is a Risky Proposition Despite Its High Valuation ↗

May 07, 2021

OCGN stock soared on a deal to commercialize Bharat Biotech’s Covaxin in the U.S., but the rollout comes with a lot of challenges.

Via InvestorPlace

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 07, 2021

Gainers Assertio Holdings (NASDAQ:ASRT) shares moved upwards by 32.42% to $0.66 during Friday's pre-market session. The company's market cap stands at $114.5...

Via Benzinga

Does Ocugen Have a Real Shot at the U.S. COVID Vaccine Market? ↗

May 07, 2021

The biotech faces some big challenges.

Via The Motley Fool

Better Vaccine Stock: Ocugen or Vaxart? ↗

May 07, 2021

Here's how the biotechs compare on several key fronts.

Via The Motley Fool

72 Biggest Movers From Yesterday ↗

May 07, 2021

Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares surged 85.8% to settle at $10.22 on above-average volume. Liquidity Services, Inc. (NASDAQ: LQDT) jumped 37.7% to settle at $25...

Via Benzinga

Ocugen Shares Sink Despite OCU200 Being Comparable To Aflibercept In Reducing Neovascularization, Damage To Retina In Animal Study ↗

May 06, 2021

Ocugen Inc (NASDAQ: OCGN) has announced the presentation of new preclinical data evaluating the efficacy of OCU200 in in-vitro and in-vivo models for ocular...

Via Benzinga

Earnings Scheduled For May 7, 2021 ↗

May 07, 2021

Companies Reporting Before The Bell • Cronos Group (NASDAQ:CRON) is likely to report earnings for its first quarter. • Eaton Vance Municipal (NYSE:ETX) is...

Via Benzinga

58 Stocks Moving In Thursday's Mid-Day Session ↗

May 06, 2021

Gainers Stealth BioTherapeutics Corp (NASDAQ: MITO) shares surged 92.9% to $2.3150. Stealth BioTherapeutics presented at the Association for Research in Vision and Ophthalmology...

Via Benzinga

OCGN Stock: Why Ocugen Shares Are Stumbling Again Today ↗

May 06, 2021

OCGN stock is tripping again on Thursday following reports of insider selling and concerns over patent waivers for Covid-19 vaccines.

Via InvestorPlace

Topics Intellectual Property

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 06, 2021

Gainers Stealth BioTherapeutics (NASDAQ:MITO) stock moved upwards by 58.33% to $1.9 during Thursday's pre-market session. The market value of their outstanding shares...

Via Benzinga

< Previous 1 2

...

29 30 31 32 33 34 35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.